Last reviewed · How we verify
Neorecormon
At a glance
| Generic name | Neorecormon |
|---|---|
| Also known as | Epoetin |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Anemia due to chemotherapy for nonmyeloid cancer
- Anemia in chronic kidney disease
- Prevention of anaemia in premature babies
Common side effects
Key clinical trials
- Vafseo Outcomes In-Center Experience (PHASE3)
- Correction of Anaemia and Progression of Renal Failure on Transplanted Patients (PHASE4)
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA. (PHASE3)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. (PHASE3)
- Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Paricalcitol Improves Anemia of Inflammation (PHASE4)
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia (PHASE3)
- Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neorecormon CI brief — competitive landscape report
- Neorecormon updates RSS · CI watch RSS
- Centre Hospitalier Universitaire, Amiens portfolio CI